Chen Cairen, Wang Weili, Meng Qingyong, Wu Ning, Wei Jun
School of Clinical Laboratory Science Guangdong Medical University Dongguan China.
Department of Radiation Oncology Augusta University GA USA.
FEBS Open Bio. 2016 Feb 16;6(3):211-5. doi: 10.1002/2211-5463.12034. eCollection 2016 Mar.
A recent study reported that circulating antibodies to CD25-derived peptide antigens were significantly higher in patients with nonsmall cell lung cancer (NSCLC) than control subjects. The present study was, thus, undertaken to replicate the initial finding with different sample sets. An in-house ELISA was applied to determine circulating IgG antibodies to linear peptide antigens derived from CD25. A total of 111 patients with NSCLC and 216 control subjects were recruited and divided into the discovery sample (51 vs 108) and the validation sample (60 vs 108) based on the time of sampling. Student's t test showed that circulating anti-CD25 IgG levels were significantly higher in the patient group than the control group (t = 2.23, P = 0.027) and the validation sample replicated this finding (t = 3.31, P = 0.0012), generating a combined P value of 0.0004 (χ(2) = 20.8, df = 4). Fisher's combining probability revealed that patients with stage IV NSCLC had a significant increase in anti-CD25 IgG levels compared with control subjects (χ(2) = 22.1, df = 4, P = 0.0002) but those with the other three stages did not. This study suggests that circulating anti-CD25 IgG antibodies may have prognostic rather than early diagnostic values for lung cancer.
最近一项研究报告称，非小细胞肺癌（NSCLC）患者体内针对CD25衍生肽抗原的循环抗体显著高于对照受试者。因此，本研究旨在用不同样本集重复最初的发现。应用内部酶联免疫吸附测定（ELISA）法来测定针对CD25衍生线性肽抗原的循环IgG抗体。总共招募了111例NSCLC患者和216名对照受试者，并根据采样时间将其分为发现样本（51例对108例）和验证样本（60例对108例）。学生t检验显示，患者组的循环抗CD25 IgG水平显著高于对照组（t = 2.23，P = 0.027），验证样本重复了这一发现（t = 3.31，P = 0.0012），合并P值为0.0004（χ(2)= 20.8，自由度 = 4）。费舍尔合并概率法显示，与对照受试者相比，IV期NSCLC患者的抗CD25 IgG水平显著升高（χ(2)= 22.1，自由度 = 4，P = 0.0002），但其他三期患者则不然。本研究表明，循环抗CD25 IgG抗体对肺癌可能具有预后价值而非早期诊断价值。
